Literature DB >> 21756850

The changing scenario of hepatocellular carcinoma over the last two decades in Italy.

Valentina Santi1, Daniela Buccione, Antonio Di Micoli, Gianluca Fatti, Marta Frigerio, Fabio Farinati, Paolo Del Poggio, Gianludovico Rapaccini, Maria Anna Di Nolfo, Luisa Benvegnù, Marco Zoli, Franco Borzio, Edoardo Giovanni Giannini, Eugenio Caturelli, Maria Chiaramonte, Mauro Bernardi, Franco Trevisani.   

Abstract

BACKGROUND & AIMS: This study investigates whether the aetiologic changes in liver disease and the improved management of hepatocellular carcinoma (HCC) have modified the clinical scenario of this tumour over the last 20 years in Italy.
METHODS: Retrospective study based on the analysis of the ITA.LI.CA (Italian Liver Cancer) database including 3027 HCC patients managed in 11 centres. Patients were divided into 3 groups according to the period of HCC diagnosis: 1987-1996 (year of the "Milano criteria" publication), 1997-2001 (year of release of the EASL guidelines for HCC), and 2002-2008.
RESULTS: The significant changes were: (1) progressive patient ageing; (2) increasing prevalence of HCV infection until 2001, with a subsequent decrease, when the alcoholic aetiology increased; (3) liver function improvement, until 2001; (4) increasing "incidental" at the expense of "symptomatic" diagnoses, until 2001; (5) unchanged prevalence of tumours diagnosed during surveillance (around 50%), with an increasing use of the 6-month schedule; (6) favourable HCC "stage migration", until 2001; (7) increasing use of percutaneous ablation; (8) improving survival, until 2001.
CONCLUSIONS: Over the last 20 years, several aetiologic and clinical features regarding HCC have changed. The survival improvement observed until 2001 was due to an increasing number of tumours diagnosed in early stages and in a background of compensated cirrhosis, and a growing and better use of locoregional treatments. However, the prevalence of early cancers and survival did not increase further in the last years, a result inciting national policies aimed at implementing surveillance programmes for at risk patients.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21756850     DOI: 10.1016/j.jhep.2011.05.026

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  28 in total

1.  Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience.

Authors:  Mauro Borzio; Elena Dionigi; Angelo Rossini; Anna Toldi; Giampiero Francica; Fabio Fornari; Andrea Salmi; Fabio Farinati; Susanna Vicari; Massimo Marignani; Fulvia Terracciano; Barbara Ginanni; Rodolfo Sacco
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

Review 2.  Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art.

Authors:  Roberto Iezzi; Maurizio Pompili; Alessandro Posa; Giuseppe Coppola; Antonio Gasbarrini; Lorenzo Bonomo
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

3.  Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters.

Authors:  Petr Pancoska; Brian I Carr; Edoardo G Giannini; Fabio Farinati; Francesca Ciccarese; Gian Ludovico Rapaccini; Maria Di Marco; Luisa Benvegnù; Marco Zoli; Franco Borzio; Eugenio Caturelli; Maria Chiaramonte; Franco Trevisani
Journal:  Semin Oncol       Date:  2014-04-24       Impact factor: 4.929

Review 4.  Management of hepatocellular carcinoma in the elderly.

Authors:  Mauro Borzio; Elena Dionigi; Giancarlo Parisi; Ivana Raguzzi; Rodolfo Sacco
Journal:  World J Hepatol       Date:  2015-06-18

5.  Role of ablation: should it be used as primary therapy for early-stage hepatocellular carcinoma?

Authors:  Maurizio Pompili; Giampiero Francica
Journal:  Hepat Oncol       Date:  2015-11-06

Review 6.  Disease Burden of Hepatocellular Carcinoma: A Global Perspective.

Authors:  Mehmet Sayiner; Pegah Golabi; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

7.  Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits.

Authors:  Sara Boccalini; Cristina Taddei; Vega Ceccherini; Angela Bechini; Miriam Levi; Dario Bartolozzi; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2013-02-01       Impact factor: 3.452

Review 8.  Ablation therapy for hepatocellular carcinoma: past, present and future perspectives.

Authors:  David J Niemeyer; Kerri A Simo; David A Iannitti; Iain H McKillop
Journal:  Hepat Oncol       Date:  2013-12-20

9.  Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.

Authors:  Andrea L Inghilesi; Donatella Gallori; Lorenzo Antonuzzo; Paolo Forte; Daniela Tomcikova; Umberto Arena; Stefano Colagrande; Silvia Pradella; Bernardo Fani; Elena Gianni; Luca Boni; Giacomo Laffi; Francesco Di Costanzo; Fabio Marra
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

10.  Total tumor volume predicts survival following liver resection in patients with hepatocellular carcinoma.

Authors:  Mu-Xing Li; Hong Zhao; Xin-Yu Bi; Zhi-Yu Li; Zhen Huang; Yue Han; Jian-Guo Zhou; Jian-Jun Zhao; Ye-Fan Zhang; Wen-Qiang Wei; Dong-Bin Zhao; Jian-Qiang Cai
Journal:  Tumour Biol       Date:  2016-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.